The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
The plan is to advance innovative therapies to drug-resistant cancers
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The announcement follows FDA 510(k) clearance of device
As a global mushroom biotechnology group, Mycelium Biotechnology is engaged in mushroom growing, global distribution and offering biotechnology and nutraceutical solutions through global partners
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Subscribe To Our Newsletter & Stay Updated
